VRTX
$462.49
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
Intraday
Recent News
Is Crispr Therapeutics (CRSP) The Best Gene-Editing Stock to Buy Now?
Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr Therapeutics Ag (NASDAQ:CRSP) shares are up 16% over the past 12 months. Cathie Wood’s ARK increased its stake in the company by 8% in the fourth quarter, entering 2026 with a $10.5 million position. Crispr […]
1 Momentum Stock to Research Further and 2 We Ignore
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Is Vertex Pharmaceuticals Heading to $600?
A new product approval may be right around the corner.
Vertex Data Sharpen Focus On Kidney And Pain Revenue Mix
Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive Phase 3 RAINIER data for povetacicept in IgA nephropathy, meeting primary and secondary endpoints with strong efficacy and safety. The company is preparing a Biologics License Application for povetacicept, seeking accelerated FDA review using a priority review voucher. New Phase 4 results for JOURNAVX, suzetrigine, showed support for opioid free recovery across a range of surgical procedures. Vertex is advancing povetacicept into...
This Stock Just Jumped By 8%: Is It Too Late to Buy?
The drugmaker is getting its mojo back.